Martin Murphy - Life Sciences

Martin is the Chief Executive Officer of Syncona Investment Management Ltd and co-founder of Syncona Partners LLP. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare investments. During his time at MVM, Martin was a member of the Management and Investment Committees and led MVM’s European operations. He was involved in a number of investments including PregLem SA (sold to Gedeon Richter), Momenta Pharmaceuticals, Inc, (NASDAQ: MNTA), Healthcare Brands International (sold to Meda AB) and Heptares Therapeutics Ltd (sold to Sosei Group Corporation). Before MVM, Martin had roles with 3i Group plc and McKinsey & Company. Martin has a PhD in Biochemistry from Cambridge University.

Chris Hollowood - Life Sciences

Chris is the Chief Investment Officer and a Managing Partner of Syncona Investment Management Ltd. Previously, he was a partner of Apposite Capital LLP, a venture and growth capital company focused on the healthcare and life science sector.

During his time at Apposite, he was involved in a number of investments, which included Ambit Biosciences (acquired by Daiichi Sankyo), Convergence Pharmaceuticals (acquired by Biogen-Idec), Birdrock and the acquisition of a portfolio of nine US healthcare companies which included Zonare Medical Systems (acquired by Mindray) and Ulthera (acquired by Merz). Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and as a medicinal chemist in the pharmaceutical industry.

Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from Cambridge University

John Bradshaw - Life Sciences

John Bradshaw is the Chief Financial Officer of Syncona Investment Management Ltd. He has worked extensively with companies in the life sciences sector as a part time and interim CFO. He was previously CFO of Gyrus Group PLC and qualified as a Chartered Accountant with Arthur Andersen.

John has a degree in Law from the University of Liverpool.

Iraj Ali - Life Sciences

Iraj is a Managing Partner of Syncona Investment Management Ltd. Previously; he was an associate-principal at McKinsey & Company where he specialised in product launch. He has been involved in several major pharmaceutical launches across developed and emerging markets and was a co-founder of McKinsey’s US launch practice and leader of speciality launch in Europe. Prior to joining McKinsey Iraj held roles in scientific research: EMBO Research Scholar (UCSC), Drug Discovery Scientist (RiboTargets, Cambridge).

Iraj has a PhD in Biochemistry from Cambridge University.

Arabella Cecil - Funds

Arabella is Head of Funds Investments for Syncona. Arabella started working in financial services in 1987, for Finbancaria (corporate finance, Milan), and later Banque Hottinguer (Paris), and Credit Lyonnais Laing (London) where she was head of food manufacturing research. Between 1998 and 2008 she owned and ran Gravity Pictures, which specialised in filmmaking in the IMAX® format. Most recently she was an investment manager and a member of the investment and risk committees of Culross Global Management.

Toby Sykes - Life Sciences

Toby is a Managing Partner of Syncona Investment Management Ltd. Previously he was a Managing Director at Essex Woodlands, a healthcare venture capital and growth equity company. Whilst at Essex Woodlands, Toby led the firm’s pharmaceuticals practice, and was responsible for investments in Europe and Latin America. He was involved in a number of investments, including EUSA Pharma (sold to Jazz Pharma), Molecular Partners (SWX:MOLN) and Healthcare Brands International (sold to Meda). Previously, Toby was a Director of Business Development at Cephalon. He has a PhD in Development Biology from King’s College London.

Edward Hodgkin - Life Science

Ed is a Partner of Syncona Investment Management Ltd. He is a Director of Syncona’s portfolio company, Autolus, where he served as Chief Executive Officer from the company’s inception in September 2014 until March 2016. Prior to joining Syncona, he was Chief Executive Officer of Biotica Technology Ltd (Cambridge, UK) from 2007 to 2012. Ed spent 12 years in the US, serving as President & Chief Business Officer of BrainCells, Inc. (San Diego, CA) and Vice President, Business Development & Marketing at Tripos, Inc. (St. Louis, MO). He has broad deal-making experience, including licensing, strategic alliances, company formation and equity financing. His early career was spent in scientific and management roles at Wyeth-Ayerst, Inc. (Princeton, NJ) and British Biotech Ltd. (Oxford, UK). Ed holds an MA and DPhil in Chemistry from Oxford University and is a former Chairman of the BioIndustry Association (BIA)

Elisa Petris - Life Sciences

Elisa is a Partner of Syncona Investment Management Ltd. Previously; she was a Senior Associate at boutique investment bank Michel Dyens & Co. where she worked on a number of transactions covering the healthcare space. Prior to joining Michel Dyens & Co., Elisa was a member of the European Life Sciences and Healthcare team at strategy consultancy firm L.E.K. Consulting based in London. During her time at L.E.K. she worked on a broad range of projects for Biotech, Pharma and Private Equity clients.

Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.

Magdalena Jonikas - Life Sciences

Magdalena is a Partner of Syncona Investment Management Ltd. Previously, she was an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing. Magdalena holds a PhD in Bioengineering from Stanford University and was a postdoctoral fellow in Harvard Medical School’s Computational Health Informatics Programme.

Chris Ashton - Life Sciences

Chris is a Partner of Syncona Investment Management Ltd and acts as Chief Executive Officer of Syncona’s portfolio company, Achilles Therapeutics.  He is a seasoned biotech entrepreneur with over 30 years’ experience in the industry. From 2004, he served at the Chief Executive Officer of Argenta Discovery Ltd. (acquired by Galapagos NV in 2010) and its successor company, Pulmagen Therapeutics Limited. During this time, he successfully transitioned the company from an early stage drug discovery company to a mid-stage clinical development organisation. He has considerable expertise in leading and growing early stage companies and extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity.

Chris holds a PhD in organic chemistry from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).

Dominic Schmidt - Life Sciences

Dominic is a Partner of Syncona Investment Management Ltd. Prior to joining Syncona, he was a member of the life science team at strategy consultancy L.E.K. Consulting, where he worked on a variety of strategy projects for Biotech, Pharma and Healthcare companies. Dominic received his Ph.D. from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom Degree in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics. His research has been honoured with national and international prizes and published in Cell, Nature and Science.

Alex Hamilton - Life Sciences

Alex is a Partner of Syncona Investment Management Ltd. Previously, he was a member of the Healthcare Investment Banking team at Jefferies, where he worked on a range of financings and mergers and acquisitions across the biotechnology, pharmaceutical and healthcare sectors. Alex has a PhD in Immunology from Cambridge University.

Hitesh Thakrar - Life Sciences

Hitesh is a Partner of Syncona Investment Management Ltd. He is an experienced investor in the sector, having spent over 20 years investing in public global equities in the life sciences, technology and the innovation sectors.

He has worked at various institutions in equity research and Fund Management from ADIA, the sovereign wealth Fund of Abu Dhabi, JP Morgan, Aviva Group, Dresdner Bank and New Star Asset Management. He has a strong track record, rated AA manager and was also a top 1 percentile manager in global equities. He is on the Board of Desktop Genetics, a CRISPR IP library company, backed by Illumina and is an angel investor in early stage Innovation companies. He is also on the Investment Committee of the LBA Scale Up Innovation Fund.

Hitesh holds a degree in Chemistry from Kings College, London, MBA from Cranfield University and CFA, the American Association of Investment Analysts.

Andrew Cossar - Life Sciences

Andrew is the General Counsel of Syncona Investment Management Ltd.  Previously he was Chief Investment Counsel at the Wellcome Trust, responsible for legal issues arising from its £23bn global multi-asset investment portfolio, and where he was involved in the initial formation of Syncona Partners LLP.  Prior to that he worked as a corporate lawyer in London and Edinburgh.

Andrew has an LLB from the University of Glasgow.

Nikki Padden - Life Sciences

Nikki is the Head of Finance of Syncona Investment Management Ltd.  She is a chartered accountant (ICAEW) with experience in both practice and commerce.  Previously she worked in the biopharmaceutical industry in various roles, including business operations at GlaxoSmithKline and project management for AEA Technology’s biosciences division and its contract manufacturing spin-out. Prior to this she worked in research at King’s College, London and the University of Reading.

Nikki has a PhD in Biotechnology from King’s College, London and an MBA from Warwick Business School.

Philip Bassett

Philip oversees Syncona’s Investor Relations program. Previously, Philip worked for over 20 years at Permira, a Private Equity firm focused on larger transactions across a number of sectors where he was the partner in charge of the investor side of the business and led its fundraising activities Philip has a degree in Classics from Oxford University and is a Chartered Accountant.

Siobhan Weaver - Life Sciences

Siobhan Weaver is Head of Investor Relations and Communications at Syncona. Previously, spent 6 years in financial communications in the UK and Australia advising across sectors on a wide range of projects and transactions. She has degrees in Law and Media Communications from the University of Melbourne.

Ross Carswell - Life Sciences

Ross is the Fund and Financial Accountant of Syncona Investment Management Limited. Ross became a chartered accountant (ICAEW) on PwC’s fast track programme, with experience in both practice and commerce. Ross has a Business, Accounting and Finance degree from Newcastle University.

Fiona Fernandez - Life Sciences

Fiona is the Office Manager of Syncona Investment Management Ltd overseeing the daily operations of the office and supporting a number of the partners. Prior to joining Syncona, Fiona held various senior support roles, most recently as an Executive Assistant at AnaCap Financial Partners, supporting two of the Partners, Legal Counsel and the Mergers and Acquisitions team.

Fiona holds a degree in Geography and Management from Leeds University.